WellCare of Kentucky and Centene Foundation, the philanthropic arm of Centene Corp., today announced an investment of $550,000 to launch the WellCare Food is Medicine Program to address ...

GLP-1 medications, such as Ozempic, Zepbound and Wegovy, have emerged as a significant advancement in the treatment of various conditions, including Type 2 diabetes, heart ...

Forbes contributors publish independent expert analyses and insights. Jesse Pines is an expert in healthcare innovation and wellness. This voice experience is generated by AI. Learn more. This voice ...

President Trump's new TrumpRx online platform is a key part of his plan to help lower drug costs for consumers, with some polls showing two-thirds of Americans report high health care costs as their ...

TrumpRx, the Trump administration's much-anticipated direct-to-consumer drug platform, went live on Thursday. A key pillar of President Donald Trump's effort to lower prescription drug costs, the ...

This article is the latest in the Health Affairs Forefront featured topic, “Health Policy at a Crossroads,” produced with the support of the Commonwealth Fund and the Robert Wood Johnson Foundation.

Botox and the GLP-1 drug Trulicity are among the latest group of prescription drugs subject to price controls by Medicare. The Centers for Medicare & Medicaid Services (CMS), the federal agency that ...

While the 15 medications selected for the latest round of the federal government’s drug price negotiation program will face steep cuts in what Medicare will pay, the financial impact to pharmaceutical ...

The Centers for Medicare & Medicaid Services has announced the selection of 15 prescription drugs for the third cycle of the Medicare Drug Price Negotiation Program. These are high-cost drugs covered ...

Pharmaceutical companies hiked prices on hundreds of drugs so far in January, ushering in 2026 with steeper costs for everything from the COVID-19 vaccine to Ozempic despite the Trump administration's ...

Since September, 16 major drug companies have inked deals with the Trump administration to lower prices. But in January — the time of year when pharmaceutical companies typically roll out price hikes ...

Several common drugs will be cheaper next year under Medicare, from weight-loss drug Ozempic to breast-cancer medication Ibrance, according to the Centers for Medicare & Medicaid Services (CMS). The ...